Business
TNI BioTech, Inc. through its wholly owned subsidiary TNI BioTech International Ltd., provides progress report on bridging trial for HIV/AIDS in Nigeria
TNI BioTech, Inc. through its wholly owned subsidiary TNI BioTech International Ltd., provides progress report on bridging trial for HIV/AIDS in Nigeria.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nTNI BioTech, Inc. through its wholly owned subsidiary TNI BioTech International Ltd., provides progress report on bridging trial for HIV/AIDS in Nigeria\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTNI BioTech, Inc. through its wholly owned subsidiary TNI BioTech International Ltd., provides progress report on bridging trial for HIV/AIDS in Nigeria\nPR Newswire\nORLANDO, Fla. and DUBLIN, Dec. 4, 2014\n\n\n\nORLANDO, Fla. and DUBLIN, Dec. 4, 2014 /PRNewswire/ -- TNI BioTech, Inc., (OTC-TNIB) (the \"Company\"), a specialty pharmaceutical company involved in the manufacture, distribution and marketing of novel, immunotherapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, announced the finalization of logistics and patient recruitment for the initiation of the Company's 90-day bridging trial in Nigeria of Lodonal™ in patients with HIV/AIDS.\n\nNoreen Griffin, the Company's CEO, said, \"This approval is the most important step we have accomplished this year as it launches the last clinical bridging trial before potential market authorization in Nigeria. We believe Lodonal™ will offer meaningful clinical benefit for patients with HIV/AIDS where there continues to be serious unmet medical needs. We believe this is the first step in providing an affordable, easy to administer, immune therapy into emerging nations.\" \n\nThe Commissioner of Health and Permanent Secretary gave final patient approval from the Ministry of Health from Osun State Government for the 90-day trial. In coordination with the Nigerian National Agency for Food and Drug Administration and Control (\"NAFDAC\"), the Osun State Research and Ethics Committee (\"OSHREC\") will oversee all aspects of the 90-day trial.  It is expected that quantitative data that includes CBC with differentials, CMP, CD4 and alpha-interferon and qualitative data that is based on the Company's developed questionnaire, will be collected on Day 1, Day 45 and Day 90 of the trial. \n\nDr. Gloria B. Herndon, a consultant for the Co...